Semaglutide Use in Elderly Obese Patients

Part of paid clinical trials in Buffalo, New York.

Sponsor
State University of New York at Buffalo
Study ID
NCT05302596
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
65 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Semaglutide Pen Injector — DRUG
    semaglutide (up to 1mg) once weekly injection added to the standard of care weight loss program. Semaglutide dose will be started at 0.25 mg dose during the baseline visit and doubled every 2 weeks up to 1mg dose or up to maximum tolerable dose for total of 16 weeks of intervention

Study Details

This is a single-center, prospective, controlled, randomized and open label study to investigate the effect of the semaglutide addition to standard of care weight loss intervention (personalized lifestyle and exercise) in elderly obese subjects on body weight and body composition as assessed by DEXA.

Key Dates

Start date
Sep 1, 2022
Status verified
Mar 2025
Primary completion
Oct 23, 2023
Completion
Oct 30, 2024

Study Design

Enrollment
16 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Semaglutide
    Semaglutide, added to standard of care, starting dose of 0.25mg titrated up to 1mg dose. for a total of 16 weeks.
  • No Intervention: standard of care only
    Standard of Care (SOC) weight loss intervention alone (personalized lifestyle and exercise)

Primary Outcome Measure

Body Composition as Total Fat Mass/ Total Fat-free Mass Ratio [ Time Frame: 16 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Diabetes and Endocrinology Research CenterBuffaloNew York14221-

Related coverage on Hipa.ai

Find similar trials in Buffalo, NY

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Diabetes and Endocrinology Research Center· Buffalo, NY

Related Studies